FR15C0030I1 - - Google Patents
Info
- Publication number
- FR15C0030I1 FR15C0030I1 FR15C0030C FR15C0030I1 FR 15C0030 I1 FR15C0030 I1 FR 15C0030I1 FR 15C0030 C FR15C0030 C FR 15C0030C FR 15C0030 I1 FR15C0030 I1 FR 15C0030I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46198803P | 2003-04-11 | 2003-04-11 | |
PCT/US2004/011106 WO2004091502A2 (fr) | 2003-04-11 | 2004-04-09 | Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0030I1 true FR15C0030I1 (fr) | 2015-05-22 |
FR15C0030I2 FR15C0030I2 (fr) | 2015-07-24 |
Family
ID=33299886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0030C Active FR15C0030I2 (fr) | 2003-04-11 | 2015-04-21 | Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies |
Country Status (30)
Country | Link |
---|---|
US (17) | US6992096B2 (fr) |
EP (9) | EP3889142B1 (fr) |
JP (2) | JP4851933B2 (fr) |
KR (1) | KR101134188B1 (fr) |
CN (2) | CN104056278B (fr) |
AU (1) | AU2004229487B9 (fr) |
BE (1) | BE2015C025I2 (fr) |
BR (1) | BRPI0409319B8 (fr) |
CA (1) | CA2521992C (fr) |
CR (1) | CR8086A (fr) |
CY (6) | CY1115870T1 (fr) |
DK (7) | DK3103800T3 (fr) |
EA (1) | EA009120B1 (fr) |
ES (7) | ES2624610T3 (fr) |
FR (1) | FR15C0030I2 (fr) |
HK (4) | HK1093979A1 (fr) |
HU (7) | HUE031794T2 (fr) |
IL (2) | IL171343A (fr) |
LU (1) | LU92698I2 (fr) |
MA (1) | MA27802A1 (fr) |
MX (1) | MXPA05010747A (fr) |
NO (2) | NO332843B1 (fr) |
NZ (1) | NZ543263A (fr) |
PL (7) | PL3549936T3 (fr) |
PT (7) | PT3103800T (fr) |
SI (7) | SI3345895T1 (fr) |
TR (1) | TR201706226T4 (fr) |
UA (1) | UA84420C2 (fr) |
WO (1) | WO2004091502A2 (fr) |
ZA (1) | ZA200508298B (fr) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458538B1 (en) * | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
US7291461B2 (en) * | 2002-06-21 | 2007-11-06 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay |
EP1543157A4 (fr) * | 2002-07-24 | 2006-11-15 | Ptc Therapeutics Inc | Methodes destinees a identifier des petites molecules modulant la terminaison de traduction prematuree et la degradation de l'arnm induite par mutation non-sens |
ES2624610T3 (es) * | 2003-04-11 | 2017-07-17 | Ptc Therapeutics, Inc. | Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
EP1815206B1 (fr) * | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Composes de suppression de non-sens et procedes de leur utilisation |
AU2012238226B2 (en) * | 2005-04-08 | 2015-05-14 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
NZ562197A (en) * | 2005-04-08 | 2010-09-30 | Ptc Therapeutics Inc | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
CN100378084C (zh) * | 2005-08-01 | 2008-04-02 | 安徽大学 | 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途 |
CA2640013A1 (fr) * | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Conjugues polymeriques de 7-ethyl-10-hydroxycamptothecine a bras multiples utilises dans le traitement du cancer du sein, du cancer colorectal, du cancer du pancreas, de l'ovaire et du poumon |
CN101505739A (zh) * | 2006-03-30 | 2009-08-12 | Ptc医疗公司 | 由具有无义突变的dna生产功能蛋白的方法以及相关疾病的治疗 |
WO2007116229A1 (fr) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Agonistes gpcr hétérocycliques |
PL3327016T3 (pl) | 2006-04-07 | 2021-10-04 | Vertex Pharmaceuticals Incorporated | Wytwarzanie modulatorów transporterów posiadających kasetę wiążącą ATP |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2007130499A2 (fr) * | 2006-05-01 | 2007-11-15 | Virobay, Inc. | Agents anti-viraux |
MY148598A (en) * | 2006-09-08 | 2013-05-15 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
EP2068871B1 (fr) | 2006-09-25 | 2013-12-25 | PTC Therapeutics, Inc. | Composés d'acide 1,2,4-oxadiozole benzoïque hydroxylé,leurs compositions et leur utilisation pour une suppression non-sens |
AU2007300542B2 (en) * | 2006-09-25 | 2012-05-17 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
DK2073805T3 (da) | 2006-10-12 | 2015-06-15 | Ptc Therapeutics Inc | Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation |
AU2013219243B2 (en) * | 2006-10-12 | 2016-09-08 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
AU2016262645B2 (en) * | 2006-10-12 | 2018-05-17 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
EP2142498A2 (fr) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Composés inhibiteurs de cftr et leurs utilisations |
ES2369805T3 (es) * | 2007-06-22 | 2011-12-07 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-imidazol. |
CA2685599A1 (fr) * | 2007-07-23 | 2009-01-29 | Summit Corporation Plc | Composes pour traiter la dystrophie musculaire de duchenne |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
AR068332A1 (es) | 2007-08-03 | 2009-11-11 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
CA2699980C (fr) | 2007-08-13 | 2015-06-02 | Divergence, Inc. | Compositions et procedes pour lutter contre les nematodes |
EA201070422A1 (ru) * | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
BRPI0817597A2 (pt) | 2007-10-04 | 2015-04-07 | Merck Serono Sa | Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos |
CA2702094C (fr) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Administration d'osmolytes par canule nasale |
EP3012250B1 (fr) | 2007-11-16 | 2017-11-08 | Vertex Pharmaceuticals Incorporated | Modulateurs d'isoquinoleine de transporteurs de cassette de liaison a l'atp |
JP5595926B2 (ja) * | 2007-12-07 | 2014-09-24 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 5−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
RS55559B1 (sr) | 2007-12-07 | 2017-05-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline |
WO2010009775A1 (fr) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Dérivés d'oxindole à substitution carbamate et utilisation de ceux-ci pour traiter des maladies dépendant de la vasopressine |
CN101981027B (zh) * | 2007-12-07 | 2014-08-06 | Abbvie德国有限责任两合公司 | 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途 |
EP2623504A1 (fr) * | 2007-12-07 | 2013-08-07 | Abbott GmbH & Co. KG | Dérivés oxindoliques disubstitués en positions 5 et 6 et leur utilisation pour la préparation d'un medicament pour le traitement de maladies liées à la vasopressine |
AU2008340113B2 (en) * | 2007-12-21 | 2014-01-09 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
KR101613610B1 (ko) * | 2007-12-25 | 2016-04-19 | 깃세이 야쿠힌 고교 가부시키가이샤 | 신규한 카테콜 유도체, 그것을 함유하는 의약 조성물 및 그것들의 용도 |
JP2011511806A (ja) | 2008-02-07 | 2011-04-14 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Atoh1発現を増強する化合物 |
NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
US20100099677A1 (en) * | 2008-04-21 | 2010-04-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Thiazole Derivatives |
WO2009131956A1 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés de triazole |
WO2009131957A2 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et traitements comprenant des dérivés d'oxydiazoles |
WO2009131951A2 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés isoxazole |
WO2009131954A2 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés oxadiazole |
BR122019022071B8 (pt) * | 2008-06-09 | 2021-07-27 | Univ Muenchen Ludwig Maximilians | composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit |
AU2009271328B2 (en) * | 2008-06-24 | 2012-09-06 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
US8017555B2 (en) | 2009-02-10 | 2011-09-13 | Divergence, Inc. | Compositions and methods for controlling nematodes |
JP5620129B2 (ja) | 2009-03-19 | 2014-11-05 | 富士フイルム株式会社 | 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物 |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
EP2251437B1 (fr) | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Procédé d'identification de composés qui contrôlent l'activité translationnelle des protéines ribosomales dans l'expression mRNA différentielle |
US9040568B2 (en) | 2009-05-29 | 2015-05-26 | Abbvie Inc. | Pharmaceutical compositions for the treatment of pain |
AR076984A1 (es) | 2009-06-08 | 2011-07-20 | Merck Serono Sa | Derivados de pirazol oxadiazol |
US9849146B2 (en) * | 2009-07-20 | 2017-12-26 | Rutgers, The State University Of New Jersey | Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A |
PT2462276E (pt) * | 2009-08-05 | 2015-02-12 | Int Paper Co | Aditivo para folha de polpa de felpa seca |
EP3868377A1 (fr) | 2009-11-13 | 2021-08-25 | Receptos Llc | Modulateurs sélectifs du récepteur de sphingosine-1-phosphate et procédés de synthèse chirale |
KR101781233B1 (ko) * | 2009-11-13 | 2017-09-22 | 셀진 인터내셔널 Ii 에스에이알엘 | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 |
CN109081804B (zh) | 2010-03-25 | 2021-12-10 | 弗特克斯药品有限公司 | 环丙烷甲酰胺的固体形式 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
KR101984225B1 (ko) | 2010-04-22 | 2019-05-30 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
WO2012016930A1 (fr) | 2010-08-05 | 2012-02-09 | Universite De Droit Et Sante De Lille | Composé utile pour le traitement de maladies médiées par une mutation non-sens et composition pharmaceutique comprenant ledit composé |
WO2012027247A2 (fr) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Composition pharmaceutique à base de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yle)cyclopropane carboxamide et son administration |
US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
JP6219271B2 (ja) | 2011-06-07 | 2017-10-25 | パリオン・サイエンシィズ・インコーポレーテッド | 治療の方法 |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
US20140094465A1 (en) * | 2011-06-10 | 2014-04-03 | N30 Pharmaceuticals, Inc. | Compounds as S-Nitrosoglutathione Reductase Inhibitors |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
KR101314488B1 (ko) * | 2011-09-08 | 2013-10-07 | 중앙대학교 산학협력단 | 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도 |
ME02650B (fr) | 2011-11-08 | 2017-06-20 | Vertex Pharma | Modulateurs de transporteurs de cassette de liaison à l'atp |
UA114619C2 (uk) | 2012-01-25 | 2017-07-10 | Вертекс Фармасьютікалз Інкорпорейтед | СКЛАД 3-(6-(1-(2,2-ДИФТОРОБЕНЗО[d][1,3]ДІОКСОЛ-5-ІЛ)ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ |
EP2828249B1 (fr) * | 2012-03-23 | 2018-10-10 | The Regents of The University of California | Composés de translecture de codons de terminaison prématurés |
EP3366680B1 (fr) | 2012-05-29 | 2020-05-13 | Parion Sciences, Inc. | Amides aminés analogues de dendrimère possédant une activité de blocage du canal sodique pour le traitement de l' il sec et d'autres affections des muqueuses |
AR091655A1 (es) | 2012-07-02 | 2015-02-18 | Monsanto Technology Llc | Procesos para la preparacion de 1,2,4-oxadiazoles 3,5-disustituidos |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
NZ745659A (en) | 2012-11-02 | 2020-04-24 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
EP2931282B1 (fr) | 2012-12-13 | 2018-10-31 | Novartis AG | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens |
ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
BR112015014349A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente |
BR112015014178A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida |
CN106455571A (zh) * | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
EP3125920B1 (fr) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol ou dibromodulcitol dans le traitement du carcinome non à petites cellules des poumons et du cancer des ovaires |
PT3925607T (pt) | 2014-04-15 | 2023-09-26 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
EP3152208B1 (fr) | 2014-06-03 | 2019-05-08 | Novartis AG | Pyrimido [4,5-b]quinoline-4,5(3h, 10h)-diones comme suppresseur de mutations non-sens |
MY178379A (en) | 2014-06-03 | 2020-10-09 | Novartis Ag | Naphthyridinedione derivatives as suppressors of non-sense mutations |
EP3152207B1 (fr) | 2014-06-03 | 2019-05-08 | Novartis AG | Dérivés de pyridopyrimidinedione comme suppresseur de mutations non-sens |
CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
CN104292180A (zh) * | 2014-10-12 | 2015-01-21 | 湖南华腾制药有限公司 | 一种恶二唑衍生物的制备方法 |
WO2016073470A1 (fr) * | 2014-11-04 | 2016-05-12 | The University Of Kansas | Activateurs de l'ampk de lkb1 pour une utilisation thérapeutique dans la polykystose rénale |
WO2016073545A1 (fr) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Acides benzoïques de phényloxadiazole |
AU2015367531B2 (en) * | 2014-12-17 | 2020-04-30 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists |
CN106316885B (zh) * | 2015-07-03 | 2019-02-12 | 普济生物科技(台州)有限公司 | 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法 |
AR106530A1 (es) | 2015-10-30 | 2018-01-24 | Ptc Therapeutics Inc | Métodos para tratar epilepsia |
WO2017087364A1 (fr) | 2015-11-16 | 2017-05-26 | Ptc Therapeutics, Inc. | Analogues enrichi en isotopes d'hydrogène de composés d'acide benzoïque 1,2,4-oxandiazole, compositions et leurs utilisations |
US10898483B2 (en) | 2015-12-23 | 2021-01-26 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
TW201808922A (zh) | 2016-06-20 | 2018-03-16 | 台灣神隆股份有限公司 | 製備阿塔魯仁及其中間體的方法 |
GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King's College London | Crystalline forms of a therapeutic compound and processes for their preparation |
CN106279057B (zh) * | 2016-08-15 | 2022-04-15 | 广州明药科技有限公司 | Ataluren的合成方法 |
WO2018047139A1 (fr) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Composés modulateurs de la voie de signalisation de tigit |
EP3512516A1 (fr) | 2016-09-13 | 2019-07-24 | Marco Cipolli | Procédé de traitement du syndrome de shwachman-diamond |
WO2018187479A1 (fr) | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Procédé de modulation de la ribonucléotide réductase |
EP3641752A4 (fr) | 2017-06-22 | 2021-03-17 | Moonshot Pharma LLC | Méthodes de traitement du cancer au moyen de compositions comprenant de l'amlexanox et des immunomodulateurs |
US11795196B2 (en) | 2017-12-15 | 2023-10-24 | Stealth Biotherapeutics Inc. | Mitochondria-targeting peptides |
WO2020078894A1 (fr) | 2018-10-15 | 2020-04-23 | Academisch Medisch Centrum | Associations oncothérapeutiques |
KR102658031B1 (ko) * | 2018-12-27 | 2024-04-18 | 제이투에이치바이오텍 (주) | 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체 |
CN110987847B (zh) * | 2019-12-11 | 2021-02-19 | 苏州今蓝纳米科技有限公司 | 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用 |
CN111675672A (zh) * | 2020-05-12 | 2020-09-18 | 石家庄市度智医药科技有限公司 | 一种制备阿塔鲁伦的方法 |
CN113045510B (zh) * | 2021-03-31 | 2022-05-27 | 北京大学生命科学华东产业研究院 | 一种阿塔鲁伦的制备方法 |
EP4230196A1 (fr) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Composés à utiliser dans le traitement des dystrophinopathies |
US11932632B1 (en) | 2023-10-13 | 2024-03-19 | King Faisal University | N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound |
US11958814B1 (en) | 2023-11-02 | 2024-04-16 | King Faisal University | 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (fr) * | 1962-04-17 | |||
US3325446A (en) | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
US4016170A (en) * | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4165910A (en) * | 1977-10-25 | 1979-08-28 | Bunker Ramo Corporation | Electrical connector |
AU531759B2 (en) | 1978-04-17 | 1983-09-08 | Ici Ltd. | Electrostatic spraying |
US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
DE3173083D1 (en) | 1980-03-22 | 1986-01-16 | Fbc Ltd | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
GB9226717D0 (en) | 1992-12-22 | 1993-02-17 | Coffee Ronald A | Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
GB9406255D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6071700A (en) * | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
IL117474A (en) | 1995-03-14 | 2001-04-30 | Siemens Ag | Removable precise dosing unit containing inhaled drugs for a hearing aid device |
IL117473A (en) | 1995-03-14 | 2001-08-26 | Siemens Ag | Ultrasonic atomizer device with removable precision dosating unit |
SK30198A3 (en) | 1995-09-07 | 1998-08-05 | Novartis Ag | Substituted phosphinic compounds and their use as pharmaceuticals |
WO1997039745A1 (fr) | 1996-04-19 | 1997-10-30 | Sloan-Kettering Institute For Cancer Research | Utilisation de retinoides inhales dans la prevention du cancer |
CN1216534A (zh) * | 1996-04-26 | 1999-05-12 | 日本曹达株式会社 | 杂环取代的新颖苯衍生物和除草剂 |
DE19620041A1 (de) * | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
EP0906310A4 (fr) | 1996-06-07 | 1999-09-01 | Merck & Co Inc | BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
WO1998045263A1 (fr) | 1997-04-07 | 1998-10-15 | Georgetown University | Analogues de cocaine |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
WO1999021852A1 (fr) * | 1997-10-27 | 1999-05-06 | Nippon Soda Co., Ltd. | Nouveaux derives de benzoylpyrazole et herbicides |
IL138153A0 (en) | 1998-03-16 | 2001-10-31 | Inhale Therapeutic Syst | Methods and devices for delivering aerosolized active agents |
CA2329712A1 (fr) | 1998-04-23 | 1999-10-28 | Cortech Inc. | Inhibiteurs de cysteine proteases |
IL142388A0 (en) | 1998-10-08 | 2002-03-10 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
EP1119568B1 (fr) | 1998-10-09 | 2004-02-18 | Janssen Pharmaceutica N.V. | Derives de 4-5-dihydro-isoxazole et leur utilisation pharmaceutique |
AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
TR200101869T2 (tr) | 1998-12-23 | 2002-01-21 | Smithkline Beecham Corporation | Proteaz İnhibitörleri. |
WO2000058278A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives d'acides amines $g(b) |
AU3196100A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
AU3196300A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Carbocyclic sulfonamide derivatives |
CA2373892A1 (fr) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Antagonistes/agonistes inverses de glucagon |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
WO2001066534A2 (fr) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques |
AU4398801A (en) | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
AU2001248765A1 (en) * | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
GB0011089D0 (en) * | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
PL360495A1 (en) | 2000-05-22 | 2004-09-06 | Aventis Pharmaceuticals Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
CN1328143A (zh) | 2000-06-12 | 2001-12-26 | 上海博德基因开发有限公司 | 一种新的多肽——人甲基化-dna-蛋白-半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸 |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2342432A1 (fr) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Compose nouveau |
GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
ES2252455T3 (es) | 2001-04-19 | 2006-05-16 | Bayer Healthcare Ag | Arilsulfonamidas como agentes antivirales. |
US7041685B2 (en) * | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
JP2006502134A (ja) | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体において活性を有する化合物 |
JP2006506340A (ja) | 2002-08-09 | 2006-02-23 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体5のモジュレーターとしてのオキサジアゾール |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
WO2004085401A1 (fr) | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite |
ES2624610T3 (es) * | 2003-04-11 | 2017-07-17 | Ptc Therapeutics, Inc. | Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
WO2004110351A2 (fr) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Composes heterocycliques pour traiter le virus de l'hepatite c |
WO2005060961A2 (fr) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Nouveau traitement du reflux gastrooesophagien pathologique |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
WO2005077373A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique ii |
EP1815206B1 (fr) | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Composes de suppression de non-sens et procedes de leur utilisation |
NZ562197A (en) * | 2005-04-08 | 2010-09-30 | Ptc Therapeutics Inc | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
CN101505739A (zh) | 2006-03-30 | 2009-08-12 | Ptc医疗公司 | 由具有无义突变的dna生产功能蛋白的方法以及相关疾病的治疗 |
WO2007123848A2 (fr) | 2006-04-19 | 2007-11-01 | Brown University | Préparations thérapeutiques contenant des protéines slrp de classe i modifiées |
MY148598A (en) | 2006-09-08 | 2013-05-15 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
AU2007300542B2 (en) | 2006-09-25 | 2012-05-17 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
DK2073805T3 (da) | 2006-10-12 | 2015-06-15 | Ptc Therapeutics Inc | Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation |
WO2008127364A2 (fr) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Composés antiviraux et utilisation de ceux-ci |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
EA201070422A1 (ru) | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
CA2704049A1 (fr) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Moyens et procedes pour contrebalancer des troubles musculaires |
ES2436781T3 (es) | 2007-12-17 | 2014-01-07 | The Regents Of The University Of Michigan | Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético |
AU2009271328B2 (en) | 2008-06-24 | 2012-09-06 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
MX345158B (es) | 2008-10-07 | 2017-01-18 | Raptor Pharmaceuticals Inc | Formulaciones de fluoroquinolona en aerosol para farmacocinetica mejorada. |
RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
-
2004
- 2004-04-09 ES ES14188816.4T patent/ES2624610T3/es not_active Expired - Lifetime
- 2004-04-09 HU HUE14188816A patent/HUE031794T2/en unknown
- 2004-04-09 AU AU2004229487A patent/AU2004229487B9/en not_active Expired
- 2004-04-09 SI SI200432484T patent/SI3345895T1/sl unknown
- 2004-04-09 PT PT161706304T patent/PT3103800T/pt unknown
- 2004-04-09 DK DK16170630.4T patent/DK3103800T3/en active
- 2004-04-09 PL PL19174887T patent/PL3549936T3/pl unknown
- 2004-04-09 PT PT211691373T patent/PT3889142T/pt unknown
- 2004-04-09 DK DK19209758.2T patent/DK3632902T3/da active
- 2004-04-09 ZA ZA200508298A patent/ZA200508298B/en unknown
- 2004-04-09 SI SI200432512T patent/SI3549936T1/sl unknown
- 2004-04-09 HU HUE21169137A patent/HUE059464T2/hu unknown
- 2004-04-09 EP EP21169137.3A patent/EP3889142B1/fr not_active Expired - Lifetime
- 2004-04-09 ES ES17204895T patent/ES2770035T3/es not_active Expired - Lifetime
- 2004-04-09 PT PT192097582T patent/PT3632902T/pt unknown
- 2004-04-09 HU HUE17204895A patent/HUE047569T2/hu unknown
- 2004-04-09 MX MXPA05010747A patent/MXPA05010747A/es active IP Right Grant
- 2004-04-09 ES ES19209758T patent/ES2887054T3/es not_active Expired - Lifetime
- 2004-04-09 NZ NZ543263A patent/NZ543263A/en unknown
- 2004-04-09 US US10/822,259 patent/US6992096B2/en not_active Expired - Lifetime
- 2004-04-09 DK DK21169137.3T patent/DK3889142T3/da active
- 2004-04-09 SI SI200432445T patent/SI3103800T1/sl unknown
- 2004-04-09 PL PL21169137.3T patent/PL3889142T3/pl unknown
- 2004-04-09 SI SI200432514T patent/SI3632902T1/sl unknown
- 2004-04-09 EP EP14188816.4A patent/EP2910551B1/fr not_active Expired - Lifetime
- 2004-04-09 ES ES04759404.9T patent/ES2528195T3/es not_active Expired - Lifetime
- 2004-04-09 HU HUE19174887A patent/HUE055056T2/hu unknown
- 2004-04-09 ES ES19174887T patent/ES2881198T3/es not_active Expired - Lifetime
- 2004-04-09 DK DK14188816.4T patent/DK2910551T3/en active
- 2004-04-09 EA EA200501601A patent/EA009120B1/ru active Protection Beyond IP Right Term
- 2004-04-09 SI SI200432222T patent/SI1618098T1/sl unknown
- 2004-04-09 EP EP19209758.2A patent/EP3632902B1/fr not_active Expired - Lifetime
- 2004-04-09 KR KR1020057019319A patent/KR101134188B1/ko active IP Right Grant
- 2004-04-09 CN CN201410119475.2A patent/CN104056278B/zh not_active Expired - Lifetime
- 2004-04-09 PL PL14188816T patent/PL2910551T3/pl unknown
- 2004-04-09 SI SI200432521T patent/SI3889142T1/sl unknown
- 2004-04-09 JP JP2006509896A patent/JP4851933B2/ja not_active Expired - Lifetime
- 2004-04-09 WO PCT/US2004/011106 patent/WO2004091502A2/fr active Application Filing
- 2004-04-09 UA UAA200510644A patent/UA84420C2/ru unknown
- 2004-04-09 DK DK19174887.0T patent/DK3549936T3/da active
- 2004-04-09 EP EP17204895.1A patent/EP3345895B1/fr not_active Expired - Lifetime
- 2004-04-09 PL PL19209758T patent/PL3632902T3/pl unknown
- 2004-04-09 PL PL16170630T patent/PL3103800T3/pl unknown
- 2004-04-09 PL PL17204895T patent/PL3345895T3/pl unknown
- 2004-04-09 CN CN200480015905.0A patent/CN1802360B/zh not_active Expired - Lifetime
- 2004-04-09 DK DK17204895.1T patent/DK3345895T3/da active
- 2004-04-09 PL PL04759404T patent/PL1618098T3/pl unknown
- 2004-04-09 EP EP19174887.0A patent/EP3549936B1/fr not_active Expired - Lifetime
- 2004-04-09 TR TR2017/06226T patent/TR201706226T4/tr unknown
- 2004-04-09 EP EP17153046.2A patent/EP3178816A1/fr not_active Withdrawn
- 2004-04-09 DK DK04759404.9T patent/DK1618098T3/en active
- 2004-04-09 PT PT47594049T patent/PT1618098E/pt unknown
- 2004-04-09 BR BRPI0409319A patent/BRPI0409319B8/pt active IP Right Grant
- 2004-04-09 SI SI200432389A patent/SI2910551T1/sl unknown
- 2004-04-09 EP EP22178089.3A patent/EP4101846B1/fr not_active Expired - Lifetime
- 2004-04-09 ES ES16170630.4T patent/ES2679108T3/es not_active Expired - Lifetime
- 2004-04-09 EP EP04759404.9A patent/EP1618098B1/fr not_active Expired - Lifetime
- 2004-04-09 PT PT191748870T patent/PT3549936T/pt unknown
- 2004-04-09 CA CA2521992A patent/CA2521992C/fr not_active Expired - Lifetime
- 2004-04-09 PT PT172048951T patent/PT3345895T/pt unknown
- 2004-04-09 EP EP16170630.4A patent/EP3103800B1/fr not_active Expired - Lifetime
- 2004-04-09 PT PT141888164T patent/PT2910551T/pt unknown
- 2004-04-09 HU HUE19209758A patent/HUE055434T2/hu unknown
- 2004-04-09 HU HUE16170630A patent/HUE039026T2/hu unknown
- 2004-04-09 ES ES21169137T patent/ES2926542T3/es not_active Expired - Lifetime
-
2005
- 2005-01-24 US US11/042,652 patent/US7772259B2/en active Active
- 2005-09-29 US US11/241,700 patent/US7202262B2/en not_active Expired - Lifetime
- 2005-10-10 IL IL171343A patent/IL171343A/en active IP Right Grant
- 2005-11-09 MA MA28594A patent/MA27802A1/fr unknown
- 2005-11-10 NO NO20055314A patent/NO332843B1/no active Protection Beyond IP Right Term
- 2005-11-10 CR CR8086A patent/CR8086A/es unknown
-
2006
- 2006-03-06 US US11/370,229 patent/US7304080B2/en not_active Expired - Lifetime
- 2006-03-06 US US11/370,130 patent/US7419991B2/en active Active
-
2007
- 2007-01-08 HK HK07100245.6A patent/HK1093979A1/xx not_active IP Right Cessation
- 2007-03-14 US US11/724,408 patent/US7683082B2/en active Active - Reinstated
-
2010
- 2010-01-21 US US12/691,005 patent/US8129540B2/en not_active Expired - Lifetime
- 2010-02-17 US US12/707,404 patent/US8017636B2/en not_active Expired - Lifetime
- 2010-03-08 US US12/719,443 patent/US8227494B2/en not_active Expired - Lifetime
-
2011
- 2011-07-15 JP JP2011156613A patent/JP5436500B2/ja not_active Expired - Lifetime
- 2011-08-18 US US13/212,221 patent/US8163782B2/en not_active Expired - Fee Related
-
2012
- 2012-03-23 US US13/427,932 patent/US8299105B2/en not_active Expired - Lifetime
- 2012-06-22 US US13/530,139 patent/US8486982B2/en not_active Expired - Lifetime
-
2013
- 2013-03-11 IL IL225161A patent/IL225161A/en active IP Right Grant
- 2013-06-19 US US13/921,269 patent/US8796322B2/en not_active Expired - Lifetime
-
2014
- 2014-06-18 US US14/307,747 patent/US8975287B2/en not_active Expired - Lifetime
-
2015
- 2015-01-16 CY CY20151100039T patent/CY1115870T1/el unknown
- 2015-01-28 US US14/607,132 patent/US9205088B2/en not_active Expired - Lifetime
- 2015-02-03 NO NO2015002C patent/NO2015002I1/no not_active IP Right Cessation
- 2015-03-18 HK HK15102788.5A patent/HK1202254A1/xx not_active IP Right Cessation
- 2015-04-16 HU HUS1500021C patent/HUS1500021I1/hu unknown
- 2015-04-17 CY CY2015017C patent/CY2015017I2/el unknown
- 2015-04-20 LU LU92698C patent/LU92698I2/fr unknown
- 2015-04-20 BE BE2015C025C patent/BE2015C025I2/fr unknown
- 2015-04-21 FR FR15C0030C patent/FR15C0030I2/fr active Active
- 2015-11-13 US US14/940,345 patent/US9861617B2/en active Active
-
2016
- 2016-02-24 HK HK16102106.9A patent/HK1214253A1/zh not_active IP Right Cessation
-
2017
- 2017-05-03 CY CY20171100480T patent/CY1119001T1/el unknown
- 2017-12-04 US US15/830,405 patent/US10071081B2/en not_active Expired - Lifetime
-
2018
- 2018-07-20 CY CY20181100761T patent/CY1120446T1/el unknown
- 2018-12-21 HK HK18116432.2A patent/HK1257517A1/zh not_active IP Right Cessation
-
2020
- 2020-01-23 CY CY20201100063T patent/CY1122659T1/el unknown
-
2021
- 2021-08-30 CY CY20211100766T patent/CY1124464T1/el unknown